Healthcare is the single biggest lobbying sector in the United States, with the industry spending over $600 million on federal lobbying in 2019 alone. The connection between healthcare and lobbying is straightforward: every major player in the system, from drug companies to hospitals to insurers, hires professional advocates to shape the laws and regulations that determine how medicine is practiced, what treatments cost, and who pays for them. The result is an influence ecosystem with roughly eight lobbyists for every member of Congress working on health policy.
Why Healthcare Attracts So Much Lobbying
Healthcare in the U.S. is a multi-trillion-dollar industry, and the federal government is its largest customer. Medicare, Medicaid, and the Children’s Health Insurance Program funnel hundreds of billions of dollars to hospitals, doctors, insurers, and drug companies each year. A single change to a reimbursement formula or a new regulation on drug pricing can shift billions in revenue. That financial exposure gives every segment of the industry a powerful incentive to influence legislation before it’s written.
The sheer number of organizations involved is staggering. During the 2009 debate over health reform, more than 1,750 companies and organizations hired about 4,525 lobbyists to work Congress on health bills, according to a Center for Public Integrity analysis. The lobbying force more than doubled over the course of that year, from about 1,400 lobbyists in the first quarter to nearly 3,700 by the final quarter when the Senate bill was being shaped. That pattern repeats every time major health legislation is on the table.
What Each Part of the Industry Lobbies For
Pharmaceutical Companies
Drug manufacturers are consistently the heaviest spenders. One analysis found that 30 healthcare organizations accounted for 40.1% of all lobbying in the sector between 2018 and early 2020, and 18 of those were pharmaceutical or dialysis companies. Their top priority in recent years has been fighting government-negotiated drug prices. When the Inflation Reduction Act introduced a framework for Medicare to negotiate prices on certain medications, industry groups mounted an aggressive campaign against it, arguing it amounted to government price-setting rather than true negotiation.
The pharmaceutical industry’s arguments tend to focus on innovation. Groups like the Biosimilars Council warned that the law’s price controls would make it too risky for manufacturers to invest the hundreds of millions of dollars required to develop cheaper alternatives to brand-name biologic drugs. Their concern: if the government negotiates a brand-name drug’s price down near the end of its exclusivity period, any competing generic or biosimilar would need to price itself even lower, potentially below the point of economic viability. Critics counter that brand-name companies often file non-innovative patents specifically to delay competition, making these arguments self-serving.
Hospitals and Health Systems
The American Hospital Association, one of the most influential lobbying groups in Washington, focuses heavily on protecting payment levels. Its current advocacy agenda centers on safeguarding federal funding for Medicare, Medicaid, and the health insurance marketplaces. A major fight for hospitals right now involves “site-neutral” payment policies, which would pay hospitals and independent clinics the same rate for identical services. Hospitals charge more for outpatient procedures performed in their facilities, and they lobby hard to preserve those higher rates, arguing that their overhead costs are legitimately different from those of a freestanding clinic.
Hospitals also lobby to maintain Medicaid Disproportionate Share payments, which compensate facilities that serve large numbers of uninsured and low-income patients. For many rural and safety-net hospitals, these payments are the difference between staying open and closing.
Insurance Companies
Health insurers concentrate much of their lobbying on Medicare Advantage, the privately run alternative to traditional Medicare that now enrolls more than half of all Medicare beneficiaries. The federal government pays insurers a set amount per enrollee, adjusted for how sick that person is. Insurers lobby to keep those payments high, arguing that cuts would force them to reduce the extra benefits (dental, vision, hearing, reduced premiums) that make their plans attractive. In practice, analysis from the Kaiser Family Foundation suggests that when payments have been trimmed, insurers have mostly absorbed the hit by reducing profits or administrative costs rather than cutting popular benefits.
Doctors and Medical Associations
The American Medical Association and specialty physician groups focus on the Medicare payment formula that determines how much doctors are reimbursed for each service. Physician payments are calculated using a relative value system that weights every procedure and adjusts for geographic cost differences. The AMA lobbies for annual payment increases to keep pace with inflation, and it recently secured a 3.26% increase for most physicians in 2026. The AMA also pushes to reform prior authorization, the process by which insurers require approval before covering certain treatments, which physicians say creates delays and unnecessary administrative burden.
Medical Device Manufacturers
Device companies spent $86 million lobbying in a single three-year period (2009 to 2011), pushing to streamline the FDA approval process. Their legislative wish list has included proposals to change the FDA’s mission to include job creation, which critics said would reduce the scrutiny given to device safety. Other proposals sought to weaken the “substantial evidence” standard the FDA uses when reviewing products. The tension here is between faster access to new technologies and rigorous safety oversight.
Pharmacy Benefit Managers: A Newer Battleground
Pharmacy benefit managers, or PBMs, are the middlemen who negotiate drug prices between manufacturers, insurers, and pharmacies. They’ve become a major lobbying force as Congress and federal agencies push for more transparency in how they operate. PBMs collect rebates from drug manufacturers, charge plans one price while reimbursing pharmacies a lower amount, and recoup fees from pharmacies after the fact. Until recently, none of this had to be disclosed.
The Department of Labor has proposed a rule requiring PBMs to disclose their compensation to the self-insured health plans they serve, including manufacturer rebates, spread pricing (the gap between what a plan pays and what the pharmacy receives), and clawback fees from pharmacies. The rule would also give plan administrators the right to audit those disclosures. PBMs have lobbied to limit the scope of such transparency requirements, while employers and consumer groups have pushed for even broader disclosure.
The Revolving Door Between Government and Industry
Lobbying in healthcare isn’t just about money. It’s also about relationships. A study published in Health Affairs found that nearly one-third of political appointees to the Department of Health and Human Services leave their government posts for jobs in the private healthcare sector. At some agencies, the numbers are even more lopsided. More than half of appointees to the Centers for Medicare and Medicaid Services, the agency that oversees insurance programs covering over 150 million Americans, departed for industry positions. At the CDC, 54% of appointees left for private-sector roles, even though only 8% had come from industry in the first place.
This revolving door matters because former officials bring with them deep knowledge of regulatory processes, personal relationships with current decision-makers, and an understanding of which arguments resonate inside government. A former Medicare administrator who now works for an insurance company doesn’t just know the policy. They know which staffers draft the rules and what those staffers care about.
How Lobbying Shapes What You Pay
The practical effect of healthcare lobbying shows up in your bills, your insurance options, and the medications available to you. When drug companies successfully delay price negotiation, patients continue paying higher prices at the pharmacy counter. When hospitals preserve higher facility fees, your insurer passes those costs along through premiums and copays. When insurers maintain high Medicare Advantage payments, taxpayers fund benefits that may or may not deliver better care than traditional Medicare.
None of this means every lobbying effort produces a bad outcome. Hospital groups lobbying to preserve Medicaid funding help keep safety-net facilities open. Physician groups pushing back on prior authorization reduce delays in patient care. The challenge is that the organizations with the most money to spend on lobbying don’t always represent the interests of patients. The 4,525 lobbyists working health reform in 2009 weren’t there to advocate for the people sitting in waiting rooms. They were there to protect revenue streams, and the policies that emerged reflected those priorities alongside, and sometimes instead of, the public interest.